What Do You Know About Oxervate?

< Back to Homepage

Oxervate Clinical Trial Results

In this video, Clifford Salinger, MD, asks W. Barry Lee, MD, FACS, to talk efficacy and safety. Dr. Lee provides an overview of the findings from various clinical trials of patients with neurotrophic keratitis treated with Oxervate (cenegermin) by Dompé Farmaceutici.


More Videos


Supplement

Supplement Cover

Breakthrough Therapy for Neurotrophic Keratitis

Marjan Farid, MD; Christopher J. Rapuano, MD; Kenneth A. Beckman, MD; Francis S. Mah, MD; and Marguerite B. McDonald, MD, share their experiences diagnosing and treating neurotrophic keratitis (NK) with Oxervate (cenegermin-bkbj). The physicians discuss common etiologies that lead to NK, what leads them to suspect the disease, and how Oxervate fits within current treatment options.

Read Supplement »
Beckman Headshot

Kenneth A. Beckman, MD

Farid Headshot

Marjan Farid, MD

Mah Headshot

Francis S. Mah, MD

McDonald Headshot

Marguerite B. McDonald, MD

Rapuano Headshot

Christopher J. Rapuano, MD